Ectopic Cushing Syndrome Due to Colon Cancer With Dual Morphology by Bryndis Baldvinsdottir et al.
Articles © The authors   |   Journal compilation © J Endocrinol Metab and Elmer Press Inc™   |   www.jofem.org
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction 
in any medium, provided the original work is properly cited
153
Case Report J Endocrinol Metab. 2014;4(5-6):153-154
ressElmer 
Ectopic Cushing Syndrome Due to Colon Cancer With Dual 
Morphology
Bryndis Baldvinsdottira, Jon G. Jonassonb, c, Uggi P. Agnarssonc, d, Helga A. Sigurjonsdottirc, e, f
Abstract
We report a case of colon cancer, and the most interesting presenta-
tion was Cushing’s syndrome (CS). A 72-year-old woman was diag-
nosed with CS when admitted to hospital because of NSTEMI and 
heart failure. The patient succumbed to her illness only 4 weeks after 
presentation. The colon cancer was a combined adenocarcinoma and 
small cell carcinoma, solely the latter component responsible for pro-
ducing adrenocorticotropin hormone (ACTH).
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Introduction
Ectopic secretion of adrenocorticotropin hormone (ACTH) is 
a rare cause of Cushing’s syndrome (CS), and when diagnosed 
the primary tumor is most often lung cancer. Colon cancer as a 
cause is extremely rare in spite of being among the most com-
mon malignancies in the general population.
To our knowledge, there are only 10 [1-3] reported cases 
of ACTH-secreting colon cancer cases in the literature.
Case Report
A 72-year-old Caucasian woman was admitted to the cardi-
ology ward at Landspitali University Hospital in Reykjavik, 
Iceland (LSH) with NSTEMI, hypertension and heart failure 
following a 7-day stay at a primary hospital (HSU). She had 
been admitted to HSU with increased fatigue, ankle edema 
and resistant hypertension. There she was found to be hyper-
glycemic, hypokalemic and hypertensive. Medical treatment 
was without success. At arrival to LSH she had hypertension 
(169/66 mm Hg), hyperglycemia (serum glucose level 23.6 
mmol/L) and profound hypokalemia (serum potassium levels 
2.0 mmol/L), despite ongoing potassium-sparing anti-hyper-
tensive treatment (enalapril 10 mg daily, losartan 50 mg daily 
and spironalactone 50 mg daily).
She had cushingoid appearance with central obesity, 
moon-face and thinning of the skin, but not stria or hirsutism. 
The patient had been treated for hypertension for several years 
with no history of hypokalemia. Serum levels of potassium 2 
months earlier were normal. She complained of muscle weak-
ness. Serum cortisol level, measured at 16:30 pm was 2,613 
nmol/L (reference: 170 - 700 nmol/L).
Morning serum cortisol levels and plasma ACTH were 
3,113 nmol/L (reference: 170 - 700 nmol/L) and 769 ng/L (ref-
erence: 0 - 46 ng/L), respectively. After low-dose overnight, 
dexamethason suppression test (DST), with 1 mg dexametha-
sone given orally at 23:00 pm, serum cortisol level at 8:00 am 
was not suppressed, 3,416 nmol/L. A 2-day low dose DST (0.5 
mg every 6 h for 48 h) was performed without suppression of 
morning serum levels of cortisol that were 4,675 nmol/L at the 
start of the test, 4,679 nmol/L after 24 h DST and 4,919 nmol/L 
after 48 h suppression. Plasma ACTH level was 4,658 ng/L 
(reference: 0 - 46 ng/L) 24 h after the 2-day DST.
Computed tomography (CT) of the abdomen showed a 
solid tumor of uncertain etiology at the recto-sigmoid junction 
and widespread metastases in the liver and lymph nodes.
A CT of the thorax showed metastases in the lungs, and 
magnetic resonance imaging (MRI) of the pituitary gland was 
negative.
The 24 h urine sample for 5-HIAA, adrenalin, noradrena-
lin, dopamin, VMA, metanephrin and normetanephrin, was 
normal.
During the hospital stay, the patient needed high doses of 
potassium supplementation as well as anti-hypertensive and 
insulin treatment. Over the course of several days the patient’s 
state worsened. She passed away only 26 days after her first 
admittance to LSH and 33 days after she was first admitted 
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to the primary hospital. Autopsy revealed a primary tumor in 
the sigmoid colon. The tumor proved to be a combined ad-
enocarcinoma and small cell carcinoma. The adenocarcinoma 
component was a conventional colonic type adenocarcinoma. 
The small cell (neuroendocrine carcinoma) component had the 
same appearance as the well known small cell anaplastic car-
cinoma of the lung. Immunohistochemical stain of the primary 
tumor showed the adenocarcinoma to be positive for CK20. 
The small cell carcinoma was positive for neuron specific eno-
lase (NSE), chromogranin, synaptophysin and ACTH (in less 
than 5% of the SCC tumor cells) (Fig. 1). Widespread metasta-
ses were present in the body, but solely from the small cell car-
cinoma component of the tumor. Lymph node metastases were 
detected in the pericolonic, peripancreatic, para-aortical and 
mediastinal lymph nodes. Massive metastases were also pre-
sent in the liver and lungs. No abnormal growth was detected 
in the bone marrow and the megakaryocytes were normal. An 
immunohistochemical stain for ACTH was performed on one 
of the metastases, and this illustrated positive tumor cells as 
well as in the primary tumor.
Discussion
We present a very unusual type of colon cancer presenting with 
CS. The explosive progression of the disease is alarming. The 
patient passed away only 33 days following admission to a 
hospital. Two months earlier she was normokalemic, but dur-
ing the hospital period she needed large doses of potassium 
supplements by infusion. The autopsy results support the clini-
cal and radiologic findings. The colon cancer was of a very 
unusual morphologic type showing both conventional colonic 
adenocarcinoma, as well as but predominantly a small cell car-
cinoma histology. The explosive elevation of ACTH secretion 
from 769 to 4,658 ng/L in 17 days, and the resistant hyperten-
sion, hyperglycemia and hypokalemia give the impression that 
the tumor was growing at an extremely fast rate. Unfortunately 
the first plasma ACTH levels did not arrive until 1 week after 
they were taken. Retrospectively, there were some alarming 
clinical signs during the hospital admission, i.e., the extreme 
hypertension and hypokalemia. In spite of that, the extreme 
progress of the disease and the profound metastatic growth of 
the tumor indicate that earlier diagnoses during the hospital 
stay would not have changed the outcome. The symptoms of 
hypercortisolism were the clinical signs of this malignant co-
lon cancer, and possibly the myocardial infarct and heart fail-
ure were secondary to that. Apart from a similar case [1] in 
2010 there has been no report on this kind of tumor in the Eng-
lish literature in recent years. A thorough literature search for 
similar cases was performed and revealed only 10 previously 
reported cases of CS caused by ectopic ACTH producing colon 
cancer. Another astonishing factor about this case is that the 
primary colon cancer had dual morphology, both adenocarci-
noma and small cell carcinoma. Neuroendocrine tumors of the 
colon are extremely rare, estimated less than 1% of colorectal 
cancers with bad overall outcome. They behave aggressively 
as most patients have metastases at the time of diagnosis [4, 5].
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Figure 1. Biopsy from primary tumor in colon. On the left is a classic 
adenocarcinoma of colon (A) and on the right a small cell carcinoma 
(B). 
